ABN Amro Investment Solutions Sells 11,020 Shares of Zimmer Biomet Holdings, Inc. $ZBH

ABN Amro Investment Solutions trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,860 shares of the medical equipment provider’s stock after selling 11,020 shares during the period. ABN Amro Investment Solutions’ holdings in Zimmer Biomet were worth $2,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of ZBH. Rakuten Investment Management Inc. purchased a new position in shares of Zimmer Biomet during the 3rd quarter valued at about $37,307,000. Sector Gamma AS boosted its stake in shares of Zimmer Biomet by 28.0% in the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after buying an additional 24,847 shares during the last quarter. Resona Asset Management Co. Ltd. grew its holdings in Zimmer Biomet by 5.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider’s stock worth $6,197,000 after acquiring an additional 3,634 shares during the period. SG Americas Securities LLC grew its holdings in Zimmer Biomet by 29.2% during the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after acquiring an additional 13,812 shares during the period. Finally, Border to Coast Pensions Partnership Ltd raised its position in Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock valued at $35,506,000 after acquiring an additional 22,104 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.2%

NYSE ZBH opened at $96.32 on Monday. The business has a fifty day moving average price of $90.10 and a 200 day moving average price of $95.66. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The company has a market cap of $19.09 billion, a P/E ratio of 27.21, a P/E/G ratio of 1.97 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were issued a $0.24 dividend. The ex-dividend date was Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research note on Friday, January 9th. Stifel Nicolaus set a $110.00 price objective on shares of Zimmer Biomet in a report on Wednesday, November 5th. Wells Fargo & Company upped their price target on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Sanford C. Bernstein raised their price objective on Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a report on Friday, January 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.